DM-919
- Generic Name
- DM-919
A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- D2M Biotherapeutics Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT06328673
- Locations
- 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇨🇳The Cancer Institute and Hospital, Chinese Academy of Medical Sciences(CAMS), Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath